This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Myeloproliferative disorder	Janus kinase-1 (JAK-1); JAK-2; heat shock protein 90 (Hsp90)	<p>Patient tissue and cell culture studies suggest combining a JAK inhibitor with an Hsp90 inhibitor could improve treatment of myeloproliferative neoplasms (MPNs). In <i>ex vivo</i> granulocytes from patients with MPN, Jakafi ruxolitinib decreased JAK-2 signaling in treatment-naïve patients but not in patients chronically treated with the drug. In MPN cells resistant to Jakafi, an Hsp90 inhibitor decreased JAK-2 protein levels and cell viability compared with vehicle. Next steps include testing JAK inhibitors in combination with Hsp90 inhibitors in preclinical MPN models.</p> <p>Jakafi, a JAK-1 and JAK-2 inhibitor from Incyte Corp. and Novartis AG, is approved to treat myeloproliferative disorder.</p> <p>SciBX 5(33); doi:10.1038/scibx.2012.867 Published online Aug. 23, 2012</p>	Unpatented; available for licensing	<p>Koppikar, P. <i>et al. Nature</i>; published online July 22, 2012; doi:10.1038/nature11303</p> <p>Contact: Ross L. Levine, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: leviner@mskcc.org</p>